3-FMA

# Research Output: 3-FMA (3-Fluoromethamphetamine)

**Substance:** 3-FMA | PSX-0045 | IUPAC: 1-(3-fluorophenyl)-N-methylpropan-2-amine  
**Research date:** 2026-05-07  
**Readiness tier:** Sparse/emerging (< 0.3) — primarily rodent studies; no published human clinical data

---

## Chemical Identity

### Verified Data

| Property | Value | Source |
|---|---|---|
| IUPAC name | 1-(3-fluorophenyl)-N-methylpropan-2-amine | PubChem CID 58216164 [Ref 1 in registry implies structure] |
| PubChem CID | 58216164 | PubChem API |
| CAS number | 1324717-74-9 (HCl salt) | Cayman Chemical [Ref 17] |
| Molecular formula | C₁₀H₁₄FN | PubChem API |
| Molecular weight | 167.22 g/mol (free base) | PubChem API |
| InChIKey | RRVAUTPWWWFYQT-UHFFFAOYSA-N | PubChem API |
| SMILES | CC(CC1=CC(=CC=C1)F)NC | PubChem/web |

### Structural Notes

3-FMA is a fluorinated methamphetamine analog in which fluorine is substituted at the meta (3) position of the phenyl ring. It possesses a chiral center at the alpha carbon, producing R and S enantiomers; commercial samples and street product are typically sold as the racemate. No published data specifically comparing the pharmacology of the individual enantiomers was identified.

### Seed Data Discrepancies

- **SMILES, PubChem CID:** Missing from seed data — now confirmed.
- **Molecular formula and weight:** Missing from seed data — now confirmed.
- **InChIKey:** Missing from seed data — now confirmed.
- All other chemical identity data in the brief matches published sources.

**⚠ FLAG:** No enantiomer-specific pharmacology data is available in the published literature. The brief does not address stereochemistry; generation agent should note the racemate issue.

---

## Pharmacology

### Mechanism of Action

3-FMA is a substituted methamphetamine analog that functions as a monoamine releasing agent. Based on its structural class and direct rodent evidence, its primary mechanism involves:

1. **VMAT2 displacement:** Amphetamine-class compounds enter presynaptic terminals via DAT/NET, then disrupt the vesicular monoamine transporter-2 (VMAT2), redistributing monoamines from vesicles to cytoplasm (Fleckenstein et al. 2007 [Ref 12]).
2. **Reverse transport:** Elevated cytoplasmic monoamine concentrations drive efflux through DAT, NET, and SERT operating in reverse, flooding the synapse with dopamine, norepinephrine, and serotonin (Fleckenstein et al. 2007 [Ref 12]).
3. **Weak base effects:** Amphetamines alkalinize vesicular pH, further disrupting monoamine storage (Fleckenstein et al. 2007 [Ref 12]).

#### Evidence for 3-FMA Specifically

- Neurotoxicity studies confirm that 3-FMA produces **dopaminergic impairments** — decreased DA levels, decreased TH expression, decreased DAT expression, decreased VMAT2 expression, and increased DA turnover — consistent with a vesicle-displacing monoamine releasing mechanism (Nguyen et al. 2018 [Ref 2]).
- Dopamine D1 receptor activation is critically involved in both 3-FMA's rewarding properties and its neurotoxicity. SCH23390 (D1 antagonist), but not sulpiride (D2 antagonist), significantly attenuated 3-FMA-induced neurotoxicity, distinguishing its mechanistic profile from methamphetamine (where D2 receptor plays a larger role) (Nguyen et al. 2018 [Ref 2]).
- 3-FMA produced conditioned place preference and high-breakpoint intravenous self-administration in rodents, behavior driven by dopamine release in the mesolimbic system (Ryu et al. 2020 [Ref 1]).

#### Positional Isomer Comparison

- **4-FMA** (para-fluorinated isomer): Published in vitro data confirms it releases NE, DA, and 5-HT at comparable potency to MDMA, with enhanced serotonergic activity relative to unfluorinated methamphetamine. TAAR1 binding is also reported (Rickli et al. 2015 [Ref 7]).
- **4-FA, 3-fluoro-methcathinone**: Confirmed monoamine substrates at all three transporters (DAT, NET, SERT) (Eshleman et al. 2017 [Ref 15]).
- **3-FMA vs 4-FMA**: The meta (3) position is expected to produce **lower serotonergic relative to dopaminergic activity** than the para isomer. Para-substitution consistently enhances serotonergic properties in the phenethylamine class (Rickli et al. 2015 [Ref 7]). This predicts 3-FMA has a more dopamine/norepinephrine-dominant profile than 4-FMA.

**⚠ FLAG:** No published in vitro Ki, IC₅₀, or EC₅₀ values for 3-FMA at DAT, NET, or SERT have been identified. All transporter selectivity claims for 3-FMA itself rest on structural analog inference. The generation agent must label any transporter potency estimates as inferred, not substance-specific.

### Behavioral Pharmacology

#### Locomotor Stimulation (Anchondo et al. 2025 [Ref 5])
- 3-FMA produced **time- and dose-dependent locomotor stimulation** in Swiss-Webster mice.
- Peak locomotor effect: **5,905–7,758 counts**, which is comparable to methamphetamine at peak.
- ED₅₀ for locomotor stimulation: 3-FMA falls in the mid-range among fluoromethamphetamine isomers tested (rank order across all analogs: 2-FMA > methamphetamine > 3-FMA = 3-FA = 2-FMA > 4-FMA; ED₅₀ range 0.38–7.38 mg/kg across all compounds tested).

#### Discriminative Stimulus (Anchondo et al. 2025 [Ref 5])
- 3-FMA produced **full substitution** for methamphetamine in a two-lever food-maintained discriminative stimulus procedure in Sprague-Dawley rats.
- ED₅₀ for methamphetamine-like discriminative stimulus: **0.32–0.71 mg/kg** range (across fluorinated analogs; all showed comparable potency).
- This confirms 3-FMA produces interoceptive cues indistinguishable from methamphetamine.

#### Rewarding and Reinforcing Properties (Ryu et al. 2020 [Ref 1])
- **Conditioned place preference (CPP):** IP administration at 10 and 30 mg/kg produced significant place preference in mice.
- **Intravenous self-administration (FR):** Drug-taking behavior at 0.1 mg/kg/infusion during 2 hr sessions (fixed ratio schedule).
- **Progressive ratio:** High breakpoints at 0.3 and 1.0 mg/kg/infusion during 6 hr sessions — comparable to known drugs of abuse.
- **Reinstatement:** Priming injections of 3-FMA (0.4 mg/kg i.v.), METH (0.2 mg/kg i.v.), or cocaine (2.0 mg/kg i.v.) all reinstated 3-FMA-seeking behavior after extinction. This cross-reinstatement pattern mirrors that of conventional stimulants.

### Pharmacokinetics

**No published human pharmacokinetic studies for 3-FMA were identified.**

By structural analog inference from related fluorinated methamphetamines:

- **Route:** Primarily oral and intranasal (community sources [Ref 10, 11]).
- **Metabolism:** Methamphetamine-class compounds are metabolized primarily by **CYP2D6** (N-demethylation). The ring-positioned fluorine on 3-FMA may inhibit aromatic hydroxylation (a minor methamphetamine metabolic route), potentially shifting metabolism toward aliphatic routes. Studies on ring-substituted methamphetamine analogs (PMMA) confirm CYP2D6 importance for N-demethylation and aromatic hydroxylation; genetic CYP2D6 variants significantly affect exposure (Vevelstad et al. 2017 [Ref 18]).
- **Fluoro metabolite formation:** For 2-FMA, metabolic pathways include N-hydroxylation and aliphatic hydroxylation; the ring fluorine is stable to metabolic defluorination under normal conditions (Ishii et al. 2023 [Ref 8]).
- **Duration of action:** Community data places oral duration at 3–7 hours total (onset 20–60 min, peak 2–4 hr, aftereffects 6–12 hr) [Ref 10, 11]. This is broadly consistent with methamphetamine pharmacokinetics (plasma half-life ~10 hr for methamphetamine, but 3-FMA duration appears shorter, consistent with modified metabolism).

**⚠ FLAG (Safety-critical):** All pharmacokinetic claims are inferred from structural analogs. No published Tmax, Cmax, t½, bioavailability, or volume of distribution data for 3-FMA in humans exists. This must be explicitly stated in the article.

---

## History

3-FMA is a **synthetic stimulant** that was developed as a research chemical and subsequently appeared on global designer drug markets. It is not derived from any traditional plant or pharmaceutical, and has no documented therapeutic use.

**Market appearance timeline (based on regulatory notifications and web-retrieved sources [Ref 9]):**
- **Finland, ~2009:** First reported regulatory notification of 3-FMA.
- **United States, ~2011:** Regulatory or law enforcement notification.
- **China and New Zealand, 2015–2016:** Addition to controlled substance lists.
- **Europe:** Germany's NpSG (November 2016) covers substituted amphetamines including 3-FMA.

3-FMA belongs to a family of fluorinated phenethylamine NPS that arose in the early-to-mid 2010s alongside 2-FMA, 4-FA, 4-FMA, and related analogs. These were marketed online as "research chemicals" or "designer drugs," with the fluorine substitution originally serving to evade blanket scheduling of methamphetamine.

**⚠ FLAG:** No peer-reviewed source has been identified that documents a specific discovery date, synthesis origin, or founding researcher for 3-FMA. The history section must rely on regulatory notification dates and should be labeled as such.

---

## Subjective Effects

**No controlled human dosing studies exist for 3-FMA.** All subjective effect descriptions derive from community harm reduction sources (KnowDrugs [Ref 10], PsychonautWiki [Ref 11]) and are not corroborated by published clinical data.

### Effects Reported by Community Sources

**Positive/desired:**
- Euphoria
- Increased energy and alertness
- Wakefulness
- Increased sociability and communication
- Mood elevation
- Reduced appetite
- Stimulation (physical and cognitive)
- Focus enhancement
- Motivation enhancement
- Music enhancement
- Touch enhancement (tactile enhancement)

**Negative/undesired (also from community sources):**
- Appetite suppression (often undesired at high doses)
- Excessive sweating
- Bruxism (teeth grinding)
- Insomnia
- Post-stimulant depression/fatigue (aftereffects phase)
- Anxiety and irritability (especially at high doses or comedown)
- Compulsive redosing urge
- Cardiovascular effects (palpitations, abnormal heartbeat)

The seed effect profile (22 effects listed, all with missing intensity/frequency values) broadly aligns with this community-reported picture. No published controlled study evidence is available to assign intensity or frequency values.

### Duration (Community Sources [Ref 10, 11])
- **Onset:** 20–60 minutes (oral)
- **Come-up:** 30–60 minutes
- **Peak:** 2–4 hours
- **Offset:** 1–3 hours
- **After effects:** 6–12 hours
- **Total duration:** 3–7 hours

These values are consistent with and confirm the seed data in the brief. No contradictions identified.

**⚠ FLAG:** Seed data duration and dose ranges are sourced from community consensus (PsychonautWiki/KnowDrugs), not controlled clinical studies. This limitation must be disclosed in the article. Values appear internally consistent but should be labeled as community-derived.

---

## Safety & Toxicity

### Animal Lethality

Nguyen et al. (2018) [Ref 2] established that 3-FMA produces **dose-dependent mortality in mice** at i.p. doses of 40, 60, and 80 mg/kg. This is a critical finding establishing acute lethality potential, though direct translation of these rodent doses to human equivalents is not possible.

- At **40 mg/kg i.p.** (a non-universally lethal dose in this study), mice showed:
  - Significant **hyperthermia**
  - **Oxidative stress** markers
  - **Microgliosis** (microglial activation to M1 pro-inflammatory phenotype)
  - **Pro-apoptotic changes** (TUNEL-positive cells)
  - Dopaminergic impairment (↓ TH, ↓ DAT, ↓ VMAT2, ↑ DA turnover)

These neurotoxic effects were **comparable in magnitude to methamphetamine** at equimolar doses (Nguyen et al. 2018 [Ref 2]).

**⚠ FLAG (Safety-critical):** No LD₅₀ values in humans, and no human clinical toxicology data, have been published for 3-FMA. The seed data toxicity characterization ("Acute: moderate; Chronic: moderate" with the note "Inferred from pharmacological class — not sourced from literature") is consistent with the animal evidence but remains unverified against human data. Generation agent must label this accordingly.

### Human Fatalities

3-FMA has been **linked to fatalities in Finland and England/Wales** based on regulatory and forensic reports referenced in Anchondo et al. (2025) [Ref 5] and Wikipedia [Ref 9]. However, **no peer-reviewed published case reports or case series specifically documenting 3-FMA-associated human deaths were identified** in PubMed searches. This is a significant gap.

**⚠ FLAG (Safety-critical):** The fatality link is real but the published clinical documentation is absent from indexed literature. The article should note that human fatalities have been reported to regulatory bodies without citing specific peer-reviewed case reports, as none were found.

### Cardiovascular Risks

By structural analogy with methamphetamine (Annawald et al. 2024 [Ref 13]; Schep et al. 2010 [Ref 14]):
- Excessive catecholamine release → vasoconstriction, tachycardia, hypertension
- Acute risks: hypertensive crisis, arrhythmia, myocardial ischemia
- Chronic risks: cardiomyopathy, pulmonary hypertension
- Hyperthermia as a compound toxicity factor

All cardiovascular claims are inferred from methamphetamine class data, not 3-FMA-specific evidence.

### Neurotoxicity Mechanism

The dopaminergic neurotoxicity of 3-FMA proceeds via D1 receptor-dependent mechanisms (distinct from methamphetamine's larger D2 receptor involvement). The sequence is:
1. Massive dopamine release (VMAT2 displacement)
2. D1 receptor activation
3. Microglial M1 activation (neuroinflammation)
4. Oxidative stress and reactive oxygen species generation
5. Apoptotic cell death

(Nguyen et al. 2018 [Ref 2])

---

## Harm Reduction

### Dose Caution

No controlled human safety data exists. Animal studies show dose-dependent lethality. Community dose ranges (oral common: 20–35 mg) should be treated as approximate — individual sensitivity, body weight, tolerance, and route of administration all affect response.

### Hyperthermia Risk

Hyperthermia is a leading mechanism of amphetamine-class stimulant toxicity. Avoiding hot environments, maintaining hydration, and not engaging in strenuous physical activity significantly reduces acute toxicity risk (inferred from methamphetamine class data [Ref 13]).

### Stimulant Overamping Protocol

For acute stimulant intoxication presenting clinically, evidence-based management includes:
1. Behavioral intervention first: reduce external stimuli, verbal de-escalation
2. Benzodiazepines (second-line)
3. Antipsychotics (third-line)
(Tilhou et al. 2026 [Ref 16])

### Testing Recommendations

Fluorinated methamphetamine isomers (2-FMA, 3-FMA, 4-FMA) are difficult to distinguish by standard immunoassay drug screens — cross-reactivity with methamphetamine tests is expected. GC-MS or LC-MS/MS with isomer-specific reference standards is required for definitive identification (Anchondo et al. 2025 [Ref 5]; Ishii et al. 2023 [Ref 8]).

### Compulsive Redosing

The rodent self-administration data demonstrates robust reinforcing properties and reinstatement of drug-seeking behavior (Ryu et al. 2020 [Ref 1]). Compulsive redosing is a documented risk; users should be aware of rapidly escalating urges to re-dose.

### Contraindications

Based on class-level evidence:
- **MAOIs** (including moclobemide, phenelzine, selegiline, harmine, harmaline): Potentially life-threatening interaction via serotonin toxicity (serotonin syndrome) and/or hypertensive crisis. No published 3-FMA-specific interaction study found; inference from methamphetamine class.
- **Lithium:** Lowers seizure threshold in combination with stimulants.
- **Cardiovascular conditions:** Absolute contraindication given catecholamine-releasing mechanism.

**⚠ FLAG (Safety-critical):** No published drug interaction studies specific to 3-FMA exist. All contraindications are class-level inferences from methamphetamine pharmacology.

---

## Tolerance & Dependence

### Tolerance

- Community data indicates tolerance half-life of approximately **3–7 days** [Ref 10].
- Full tolerance develops with "prolonged and repeated use" [Ref 10].
- Cross-tolerance with other monoamine releasers (amphetamine, methamphetamine, MDMA) is expected by class, though no substance-specific cross-tolerance data for 3-FMA was identified.

### Dependence and Withdrawal

The closely related **3-fluoroethamphetamine (3-FEA)** — differing only in N-ethyl vs N-methyl substitution — demonstrates physical dependence potential:
- Repeated administration (1 and 10 mg/kg i.p., twice daily for 7 days) produced significant withdrawal behavior scores at 16 and 40 hours post-cessation in mice.
- Withdrawal manifested as **hyperactivity** and **depression-like behavior** (increased immobility in forced swim test).
- The study explicitly concluded: "findings indicate that 3-FEA administration may lead to physical dependence" (Jo et al. 2024 [Ref 6]).

This is the most directly applicable analog evidence for 3-FMA dependence liability. Direct 3-FMA withdrawal studies in animals have not been published.

### Abuse Liability

The evidence base clearly establishes high abuse liability for 3-FMA:
- Robust self-administration in rodents (FR and PR schedules) [Ref 1]
- High-breakpoint progressive ratio performance [Ref 1]
- Full methamphetamine-like discriminative stimulus [Ref 5]
- Reinstatement by methamphetamine and cocaine [Ref 1]

**⚠ FLAG:** No published human addiction/dependence case reports for 3-FMA were identified.

---

## Interactions

**No published drug interaction studies specific to 3-FMA exist.** All interactions are class-level inferences.

| Interaction | Mechanism | Severity | Evidence Level |
|---|---|---|---|
| MAOIs | Serotonin toxicity + hypertensive crisis from unmetabolized monoamines | Potentially fatal | Class inference only |
| SSRIs/SNRIs | Additive serotonergic effects; serotonin syndrome risk | Severe | Class inference |
| Other stimulants | Additive cardiovascular burden; hyperthermia | Severe | Class inference |
| Alcohol | May mask sedation, increase cardiovascular strain, worsen dehydration | Moderate | Class inference |
| Lithium | Lowers seizure threshold | Moderate | Class inference |
| Cannabis | Unpredictable anxiety augmentation at higher doses | Mild-moderate | Class inference |

**⚠ FLAG (Safety-critical):** Every interaction listed is inferred from methamphetamine/amphetamine class data. No 3-FMA-specific interaction data exists. Must be labeled as such in the article.

---

## Legal Status

| Jurisdiction | Status | Detail |
|---|---|---|
| Canada | Schedule I controlled substance | Since 1996; controlled as methamphetamine analog |
| China | Controlled substance | Since October 2015 |
| United Kingdom | Covered by Psychoactive Substances Act 2016 | Blanket ban on novel psychoactives; supply/production prohibited |
| Germany | Controlled under NpSG | New Psychoactive Substances Act, effective November 2016; covers substituted amphetamine family |
| United States | Not explicitly scheduled | Federal Analogue Act (FAA, 21 USC § 813) potentially applies if sold for human consumption; no explicit DEA scheduling found |
| Australia | Unclear / likely prohibited | 4-FMA is Schedule 9 (prohibited); 3-FMA specific status not confirmed |
| Sweden | Classified as hazardous goods | Under Act on Chemical Weapons (Produktsäkerhetslagen); specific scheduling date not confirmed |

Sources: Wikipedia [Ref 9]; web searches confirmed Canada 1996 and China 2015; UK PSA 2016 and Germany NpSG 2016 confirmed via secondary sources.

**⚠ FLAG:** US scheduling status is not explicitly confirmed — the Federal Analogue Act may apply but 3-FMA is not on the DEA's List of Scheduled Controlled Substances. Australia status not confirmed for 3-FMA specifically. A dedicated legal database search (DEA, TGA) would be required for definitive confirmation.

---

## Clinical Trials

**No clinical trials for 3-FMA were found on ClinicalTrials.gov.** Search returned zero results. This is expected for a Schedule I-equivalent NPS with no therapeutic applications.

---

## Community Feedback Analysis

**No community feedback was submitted in Part A2 of the brief.** No feedback items to evaluate.

---

## Gaps & Flags

### Critical Data Absent from Published Literature

1. **No human pharmacokinetic data** — Tmax, Cmax, t½, bioavailability, volume of distribution: all unknown. Stated as "not sourced from literature" in seed data.

2. **No published Ki/EC₅₀/IC₅₀ values for 3-FMA specifically** at DAT, NET, or SERT. All transporter pharmacology is inferred from structural analogs (4-FMA, 4-FA, 3-FPM).

3. **No published human case reports or case series** — the factual fatality link in Finland and England/Wales appears in regulatory and secondary sources, but no peer-reviewed clinical documentation of individual cases was found.

4. **No LD₅₀ in humans** — only dose-dependent rodent mortality data exists (Nguyen et al. 2018 [Ref 2]).

5. **No controlled human dosing studies** — dose ranges and duration data derive entirely from community harm reduction databases (PsychonautWiki, KnowDrugs).

6. **No enantiomer pharmacology** — 3-FMA has a chiral center; no R vs S pharmacology data exists.

7. **No specific metabolite identification in human samples** — only analog inference from 2-FMA and PMMA metabolism studies.

8. **No published MAOI, SSRI, or stimulant-combination interaction studies** for 3-FMA.

### Safety-Critical Flags for Human Review

- **Seed toxicity data** ("Acute: moderate; Chronic: moderate") is labeled as inferred, consistent with animal data, but not human-sourced. ✓ Flag preserved.
- **Dose data** sourced from community consensus, not clinical trials. ✓ Values appear reasonable and consistent; no contradiction found, but editorial note required.
- **Duration data** similarly community-sourced and consistent with brief. ✓ No contradiction.
- **Fatality link** documented but no peer-reviewed case reports found — generation agent should not imply false precision about fatality circumstances.
- **Legal status (US, Australia)** — not fully confirmed. Generation agent should use hedged language ("may be covered under…").

### Contradictions Between Sources

No direct contradictions were found between seed data and published sources. The oral dose ranges and duration values in the seed database match community harm reduction databases exactly.

### Structural Analog Inference Dependency

The following sections rely **primarily on structural analog inference**, not 3-FMA-specific data:
- Transporter pharmacology (DAT/NET/SERT selectivity ratios)
- Human pharmacokinetics and metabolism
- CYP enzyme involvement
- Drug interaction profile
- Cardiovascular risk profile
- Tolerance mechanism
- MAOI interaction severity

All of these must be labeled explicitly in the generated article as analog-inferred, not substance-specific findings.